Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion outlines extended cash runway into early 2028 as platform efficiency accelerates

Ooops... Something went wrong while loading this page.

Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Recursion Pharmaceuticals: Q4 Earnings Snapshot

The Salt Lake City-based company said it had a loss of 21 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...